A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (M&M)
A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (M&M)
This trial is a multicenter, international double-blind, randomized, placebo-controlled, parallel group, study in patients recently hospitalized for an acute coronary syndrome. The primary objective of this trial is to evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable CHD patients, with a documented recent ACS.
PATIENTS WITH CORNARY RISK FACTORS WITH HIGH HYPER LIPIDEMIA
YES
DR. SUSAN GRAHAM SUB INVESTIGATOR: EILEEN DAETSCH, NP
Name: MARY BONORA
Phone: 716.859.4641
Email: MBONORA@KALEIDAHEALTH.ORG